


## CLAIMS


1. 6-Deacetamido-3-decarboxy-3-hydroxymethyl-6-trifluoroacetamido-siastain B represented by the formula (I):



5


or a pharmaceutically acceptable salt thereof.

2. 3-Decarboxy-4-epi-3-hydroxymethyl-siastain B represented by the formula (V):




10 or a pharmaceutically acceptable salt thereof.

3. 6-Deacetamido-3-decarboxy-4-epi-3-hydroxymethyl-6-trifluoroacetamido-siastain B represented by the formula (X):




and a pharmaceutically acceptable salt thereof.

15 4. A process for the production of 6-deacetamido-3-decarboxy-3-hydroxymethyl-6-trifluoroacetamido-siastain B represented by the formula (I):




according to claim 1, characterized in that the process comprises:

eliminating the *N*-acetyl group from an *N*-protected or  
 5 unprotected-4,5-*O*-protected-3-hydroxymethyl-3-decarboxy-  
 siastatin B represented by the general formula (II):




wherein  $R^1$  is a hydrogen atom or an imino-protecting group,  $X^1$   
 and  $X^2$  each are a monovalent hydroxyl-protecting group, or  
 10 both  $X^1$  and  $X^2$  together denote a divalent hydroxyl-protecting  
 group, to produce an *N*-protected or unprotected-4,5-*O*-  
 protected-3-hydroxymethyl-de-*N*-acetyl-3-decarboxy-siastatin B  
 represented by the general formula (III):



15 wherein  $R^1$ ,  $X^1$  and  $X^2$  have the same meanings as above;

trifluoroacetylating the free amino group of the  
 compound of the formula (III), to produce an *N*-protected or  
 unprotected-4,5-*O*-protected-6-deacetamido-3-hydroxymethyl-6-  
 trifluoroacetamido-3-decarboxy-siastatin B represented by the


general formula (IV):



wherein  $R^1$ ,  $X^1$  and  $X^2$  have the same meanings as above;


and then eliminating the imino-protecting group ( $R^1$ ) if present, and eliminating the hydroxyl-protecting groups ( $X^1$  and  $X^2$ ) from the compound of the formula (IV).

5. A process for the production of 3-decarboxy-4-epi-3-hydroxymethyl-siastatin B represented by the formula (V):




10 according to claim 2, characterized in that the process comprises:

eliminating the hydroxyl-protecting groups ( $X^1$  and  $X^2$ ) from an *N*-protected or unprotected-4,5-*O*-protected-3-hydroxymethyl-3-decarboxy-siastatin B represented by the  
15 general formula (II):



wherein  $R^1$  is a hydrogen atom or an imino-protecting group, and  $X^1$  and  $X^2$  each are a monovalent hydroxyl-protecting group,


or both  $X^1$  and  $X^2$  together denote a divalent hydroxyl-protecting group, to produce an *N*-protected or unprotected-3-hydroxymethyl-3-decarboxy-siastatin B represented by the general formula (VI):



5

wherein  $R^1$  has the same meanings as above;


protecting both of the hydroxyl group at 3-position and the free hydroxyl group at 5-position of the compound of the formula (VI), to produce an *N*-protected or unprotected-5-O-protected-3-protected-hydroxymethyl-3-decarboxy-siastatin B represented by the general formula (VII):



wherein  $R^1$  is a hydrogen atom or an imino-protecting group,  $X^3$  and  $X^4$  each denote a hydroxyl-protecting group;


oxidizing the hydroxyl group at 4-position of the compound of the formula (VII), to produce an *N*-protected or unprotected-4-keto-5-O-protected-3-protected-hydroxymethyl-3-decarboxy-siastatin B represented by the general formula (VIII):

15



wherein  $R^1$ ,  $X^3$  and  $X^4$  have the same meanings as above;


reducing the keto group at 4-position of the compound of the formula (VIII), to produce an *N*-protected or  
 5 unprotected-4-epi-5-*O*-protected-3-protected-hydroxymethyl-3-decarboxy-siastatin B represented by the general formula (IX):



wherein  $R^1$ ,  $X^3$  and  $X^4$  have the same meanings as above;


10 and then eliminating the imino-protecting group ( $R^1$ ) if present, and eliminating the hydroxyl-protecting groups ( $X^3$  and  $X^4$ ) from the compound of the formula (IX).

6. A process for the production of 6-deacetamido-3-decarboxy-4-epi-3-hydroxymethyl-6-trifluoroacetamido-siastatin  
 15 B represented by the formula (X):




according to claim 3, characterized in that the process comprises:

providing by the process according to claim 4, an *N*-protected or unprotected-4,5-O-protected-6-deacetamido-3-hydroxymethyl-6-trifluoroacetamido-3-decarboxy-siastatin B represented by the general formula (IV):




wherein  $R^1$  is a hydrogen atom or an imino-protecting group,  $X^1$  and  $X^2$  each are a hydroxyl-protecting group, or both  $X^1$  and  $X^2$  together denote a divalent hydroxyl-protecting group;

eliminating the hydroxyl-protecting groups ( $X^1$  and  $X^2$ ) from the compound of the formula (IV), to produce an *N*-protected or unprotected-6-deacetamido-3-hydroxymethyl-6-trifluoroacetamido-3-decarboxy-siastatin B represented by the general formula (XI):




wherein  $R^1$  has the same meaning as above;

protecting both of the hydroxyl group at 3-position and the free hydroxyl group at 5-position of the compound of the formula (XI), to produce an *N*-protected or unprotected-5-O-protected-6-deacetamido-3-protected hydroxymethyl-6-trifluoroacetamido-3-decarboxy-siastatin B represented by the general formula (XII):




wherein  $R^1$  is a hydrogen atom or an imino-protecting group,  $X^5$  and  $X^6$  each are a hydroxyl-protecting group;

oxidizing the hydroxyl group at 4-position of the  
 5 compound of the formula (XII), to produce an *N*-protected or  
 unprotected-5-O-protected-4-keto-6-deacetamido-3-protected  
 hydroxymethyl-6-trifluoroacetamido-3-decarboxy-siastatin B  
 represented by the general formula (XIII):



10 wherein  $R^1$ ,  $X^5$  and  $X^6$  have the same meanings as above;

reducing the keto group at 4-position of the compound  
 of the formula (XIII), to produce an *N*-protected or  
 unprotected-5-O-protected-4-epi-6-deacetamido-3-protected-  
 hydroxymethyl-6-trifluoroacetamido-3-decarboxy-siastatin B  
 15 represented by the general formula (XIV):



wherein  $R^1$ ,  $X^5$  and  $X^6$  have the same meanings as above;

and then eliminating the imino-protecting group ( $R^1$ ) if

present, and eliminating the hydroxyl-protecting groups ( $X^5$  and  $X^6$ ) from the compound of the formula (XIV).

7. A pharmaceutical composition comprising as an active ingredient 6-deacetamido-3-decarboxy-3-hydroxymethyl-  
5 6-trifluoroacetamido-siastain B of the formula (I) as claimed in Claim 1, or 3-decarboxy-4-epi-3-hydroxymethyl-siastain B of the formula (V) as claimed in Claim 2, or 6-deacetamido-3-decarboxy-4-epi-3-hydroxymethyl-6-trifluoroacetamido-siastain B of the formula (X) as claimed in Claim 3, or a  
10 pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

8. A pharmaceutical composition according to claim 7, which is used as an anticancer agent, an antidiabetic agent or an antiobestic agent.

15 9. A glycosidase inhibitor consisting of 6-deacetamido-3-decarboxy-3-hydroxymethyl-6-trifluoroacetamido-siastain B of the formula (I) as claimed in Claim 1, or 3-decarboxy-4-epi-3-hydroxymethyl-siastain B of the formula (V) as claimed in Claim 2, or 6-deacetamido-3-decarboxy-4-epi-3-hydroxymethyl-6-trifluoroacetamido-siastain B of by the  
20 formula (X) as claimed in Claim 3, or a pharmaceutically acceptable salt thereof.

10. Use of 6-deacetamido-3-decarboxy-3-hydroxymethyl-6-trifluoroacetamido-siastain B of the formula (I) as claimed  
25 in Claim 1, or 3-decarboxy-4-epi-3-hydroxymethyl-siastain B of the formula (V) as claimed in Claim 2, or 6-deacetamido-3-decarboxy-4-epi-3-hydroxymethyl-6-trifluoroacetamido-siastain B of by the formula (X) as claimed in Claim 3, or a pharmaceutically acceptable salt thereof, in the manufacture



of a pharmaceutical composition.